DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Consensus Recommendation of “Hold” by Brokerages

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) have been given a consensus recommendation of “Hold” by the fifteen brokerages that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $13.3846.

XRAY has been the topic of a number of research reports. Mizuho cut their price objective on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday, August 3rd. Barclays dropped their target price on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating for the company in a research report on Thursday, June 4th. Barrington Research set a $15.00 price target on shares of DENTSPLY SIRONA in a report on Monday. Finally, UBS Group reduced their price target on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th.

Insider Activity

In other DENTSPLY SIRONA news, Director Brian T. Gladden bought 9,985 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were acquired at an average price of $10.02 per share, with a total value of $100,049.70. Following the purchase, the director owned 61,849 shares in the company, valued at approximately $619,726.98. The trade was a 19.25% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael J. Barber bought 15,175 shares of DENTSPLY SIRONA stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the acquisition, the director directly owned 55,943 shares in the company, valued at approximately $552,716.84. This represents a 37.22% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 35,160 shares of company stock valued at $351,179. Company insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several institutional investors and hedge funds have recently modified their holdings of the stock. First Eagle Investment Management LLC increased its stake in DENTSPLY SIRONA by 3.2% during the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after buying an additional 458,744 shares during the period. Great Hill Capital LLC purchased a new position in DENTSPLY SIRONA in the 4th quarter valued at about $8,267,000. UBS Group AG grew its stake in shares of DENTSPLY SIRONA by 63.7% during the fourth quarter. UBS Group AG now owns 1,701,980 shares of the medical instruments supplier’s stock valued at $19,454,000 after acquiring an additional 662,000 shares in the last quarter. Fiduciary Alliance LLC acquired a new stake in shares of DENTSPLY SIRONA during the first quarter valued at about $4,607,000. Finally, Skylands Capital LLC purchased a new stake in shares of DENTSPLY SIRONA during the fourth quarter worth about $1,079,000. Hedge funds and other institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Stock Up 0.1%

Shares of XRAY opened at $11.59 on Friday. The firm has a market cap of $2.31 billion, a PE ratio of -4.21, a price-to-earnings-growth ratio of 1.38 and a beta of 0.85. The company’s fifty day moving average is $11.94 and its two-hundred day moving average is $11.86. DENTSPLY SIRONA has a fifty-two week low of $9.40 and a fifty-two week high of $14.86. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The company had revenue of $898.00 million during the quarter, compared to analysts’ expectations of $889.93 million. During the same period in the previous year, the company earned $0.52 EPS. The business’s quarterly revenue was down 4.1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts forecast that DENTSPLY SIRONA will post 1.49 earnings per share for the current year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.